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Fibroblast growth factor receptors (FGFRs) are involved in many 
physiological processes as well as cancer development and progression. At 
least two splice variants (IIIb and IIIc) have been described for FGFR1-3. 
Expression switching of FGFR2IIIb to the IIIc isoform relates to epithelial to 
mesenchymal transition in human prostate and bladder cancer and leads to 
a more invasive and metastatic tumor phenotype. While extensive research 
investigated the role of FGFRs in epithelial tumors, very little is known 
about their role and expression in sarcomas.  
The hypothesis of this study was that feline injection site sarcomas 
(ISSa) and non-injection site sarcomas (non-ISSa) would have differential 
expression of the FGFRs and their splice variants. Expression levels of 
mRNA for these genes were evaluated by RT-PCR using cDNA from six cell 
lines (4 ISSa and 2 non-ISSa), eight tumor samples (5 ISSa and 3 non-ISSa) 
stored in RNA later at -80°C and forty-nine FFPE samples (39 ISSa and 10 
non-ISSa). The relative quantification was performed by normalization 
against expression of RPL17, YWHAZ and PPIA genes. No statistically 
significant difference was found for FGFR1, FGFR2IIIb, FGFR3 and FGFR4. 
FGFR2IIIc was up-regulated in ISSa if compared to non-ISSa (P=0.028). 
The present study demonstrated that FGFR2IIIc is differentially 
expressed in feline ISSa compared to non-ISSa. More research is needed to 
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evaluate if different expression levels are related to the more malignant 
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1.1 Animal welfare in veterinary oncology 
Animal welfare is a recent field which initially developed with the 
intent to define welfare criteria for farm animals and then evolved to 
encompass all animal categories, including companion animals. The origin 
of animal welfare as a science is traditionally represented by the 
publication of the Brambell Report in 1965. The report stated the „five 
freedoms‟ which were revised in 1993 by Farm Animal Welfare Council 
(FAWC):  
- Freedom from thirst, hunger and malnutrition – by ready access to 
fresh water and diet to maintain full health and vigour; 
- Freedom from discomfort – by providing a suitable environment 
including shelter and a comfortable resting area; 
- Freedom from pain, injury and disease – by prevention or rapid 
diagnosis and treatment; 
- Freedom to express normal behavior – by providing sufficient space, 
proper facilities and company of the animal‟s own kind; 
- Freedom from fear and distress – by ensuring conditions which 
avoid mental suffering. 
Animal welfare is a multifaceted issue that needs an interdisciplinary 
approach. The several definitions of welfare that have been proposed 
during the last decades are a proof of the complexity of this field (Duncan et 
al, 1995):  
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 Welfare is a broad term that embraces both the physical and mental 
well-being of the animal. Any attempt to evaluate welfare, therefore, 
must take into account the scientific evidence available concerning 
the feelings of animals that can be derived from their structure and 
function and also from  their behaviour (Brambell, 1965)  
 Welfare is a state of complete mental and physical health, where the 
animal is in harmony with its environment (Hughes, 1976)  
 The welfare of an individual is its state as regards its attempts to 
cope with its environment (Broom, 1986)  
 Animal welfare is dependent solely on the cognitive needs of the 
animals concerned (Duncan et al, 1989)  
 An animal is in a state of poor welfare only when physiological 
systems are disturbed to the point that survival and reproduction 
are impaired (McGlone, 1993)  
 Risk to an animal‟s welfare occurs when an animal experiences 
stress of such a magnitude that there is a significant diversion of the 
animals biological resources from normal function (Moberg, 1993)  
 Welfare is the animal´s perspective on the net balance between 
positive (reward, satisfaction) and negative (acute stress) 
experiences of affective states (Spruijt et al, 2001).  
Diseases and suffering compromise the state of welfare in animals. Good 
health is widely recognized as an essential condition of welfare (Carenzi et 
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al, 2009) and some authors confirm that health problems should keep a 
central role in the welfare discussion (Rushen et al, 2003).  
Cancer is one of the most common and aggressive diseases in 
companion animals as well as in humans. The related pathologic conditions 
together with the invasive treatment options such as extensive surgery, 
chemotherapy and radiotherapy cause a condition of stress to the animal 
where the welfare is gravely threatened. Animal welfare is a significant 
issue in veterinary oncology and we can identify two main goals for 
oncologic patients: the first goal is to treat and cure the disease; the second 
is to ensure an acceptable level of comfort to the patient. The use of 
species-specific appropriate doses  of chemotherapeutic agents, support of 
any induced side effects and the treatment of chronic pain which is often 
present in cancer patients show the intent to minimize the level of stress in 
veterinary oncology (Robertson, 2007; Gaynor, 2008).  
Understanding molecular pathways in cancer is essential for the 
application of new therapeutic agents which specifically target the cellular 
pathways involved in the development, progression and death of tumor 
cells. The possibility to integrate specific targeted therapies for the current 
toxic therapies used in veterinary medicine will help improve both the 
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1.2 FELINE INJECTION SITE SARCOMAS 
 
1.2.1 Origin and etiology 
 
Injection site sarcomas (ISSa) are tumors which develop at the site of 
a previous vaccination or, less frequently, of a pharmaceutical product 
injection (Esplin  et al, 1999). These tumors were first recognized and 
described at the School of Veterinary Medicine of the University of 
Pennsylvania, USA. In the early 1980s an increase of the prevalence of feline 
rabies was noticed in the USA. The consequent concerns on public health 
led the State of Pennsylvania to issue a law that required the rabies 
vaccination in cats. In 1985 the killed aluminium-adjuvanted rabies for 
subcutaneous administration and FeLV virus vaccines started to be more 
frequently administered to cats by veterinarians. In the late 1980s the 
Pathology Laboratory of the University of Pennsylvania reported an 
increased number of both injection site reactions and sarcomas from 
animals that were previously vaccinated with rabies vaccine or combined 
rabies and other vaccines (McEntee et al, 2001, Hauck, 2003).  
The possible relation between fibrosarcoma development and rabies 
vaccination was first reported by Hendrick et al in 1991. This association 
was hypothesized based on the increased incidence of fibrosarcomas at 
dorsal neck/interscapular, dorsolateral thorax, hindlimb and dorsal lumbar 
regions which are all common vaccination sites. Subsequent epidemiologic 
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studies confirmed the association between rabies and FeLV vaccinations 
and development of soft tissue sarcomas in cats. Although the true 
incidence is still unknown, the estimated incidence ranges from 1/10,000 to 
5/2000 vaccinated cats (Kass et al, 1993; Esplin et al, 1993; Hauck, 2003, 
Kobayashi et al, 2002). The average interval between vaccination and tumor 
development is approximately 26 months for rabies vaccination and 11 
months for FeLV vaccination but the interval ranges between three weeks 
and 10 years (McEntee et al, 2001).  
 Despite the large amount of research the etiology of ISSa is not 
clearly understood. The inflammatory reaction at the vaccination site that 
leads to an unregulated proliferation of fibroblasts and myo-fibroblasts, 
associated with the presence of vaccine adjuvants or components, is the 
predominant theory about the origin of ISSa (Hendrick, 1999). This theory 
is supported by the frequent presence of the inflammatory capsule or 
infiltrate in ISSa, rarely noticed in spontaneous sarcomas. Additionally, 
aggregates of neoplastic cells may be seen within granulomatous reactions.  
Growth factors have also been investigated as potential contributors 
to ISSa tumorigenesis. Immunohistochemical studies showed that platelet-
derived growth factor (PDGF), epidermal growth factor (EGF), tumor 
growth factor beta (TGF-β) and their receptors are positive in ISSa and 
negative or low positive in spontaneous fibrosarcomas (FSA) (Hendrick, 
1999; Hendrick,1998; Dambach,1996). Consistent immunoreactivity for 
PDGF has been found in lymphocytes, macrophages and neoplastic cells 
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adjacent to lymphocytic infiltrates within the injection site sarcomas. 
Lymphocytes in non-ISSa and in normal lymph nodes are instead negative 
for PDFG.  
Some studies have also shown that the c-jun, a proto-oncogene 
which encodes for the protein AP-1 and is responsible of proliferation and 
oncogenesis in vitro, is expressed in ISSa whereas not expressed in non-
ISSa.  
Hershey et al in 2000 reported a correlation between the abnormal 
expression of the tumor suppressor gene p53 gene and patient outcome. In 
normal cells, the DNA damage results in an increase of wild-type p53--
which temporarily arrests the cell cycle and allows DNA repair before 
continuing the cell replication. When the DNA damage is too extensive, p53 
triggers apoptosis avoiding the propagation of defects in the genetic code 
to progeny cells. When p53 is absent or mutated, cells are allowed to 
replicate, resulting in aberrant and potentially malignant clones (Pellegata 
et al, 1996; Vogelstein et al, 1992). Activation of p53 in normal cells may 
result by three main mechanisms: an increase of the p53 protein 
concentration either by enhanced translation or elongated half-life;  the 
transformation of the p53 protein from a latent to an active conformation; 
and the translocation of the p53 protein from the cytoplasm to the nucleus. 
Cytoplasmic expression of p53 may represent a functional inactivation 
pattern. Inability of p53 to translocate to the nucleus prevents its trans-
activating function, and subsequently its ability to act as a suppressor. 
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Cytoplasmic expression of p53 has also been reported in several human 
cancers and has been correlated with a poor prognosis in colorectal cand 
breast cancer. In ISSa the cytoplasmic expression of p53 was related to a 
shorter time of local tumor recurrence (135 days) compared to cats with 
nuclear expression of p53 (325 days) (Hershey et al, 2005). 
 
1.2.2 Histological features 
 
The main histological category of ISSa is the fibrosarcoma. 
Osteosarcoma, liposarcoma, rhabdomyosarcoma, myxosarcoma, 
condrosarcoma, undifferentiated sarcoma and malignant fibrous 
histiocytoma have also been reported as histologic variants (Esplin et al,, 
1996; Hendrick et al, 1994).  
A study was conducted in 1996 by Doddy et al. to determine the 
differences between sarcomas at injection sites and non injection sites. 
Several distinctive criteria were depicted in tumor location (subcutaneous 
for ISSa and dermal for non-ISSa involving the skin); necrosis (more 
frequently noticed in ISSa); mitotic index (higher in ISSa); inflammatory 
reaction (frequent in ISSa); pleomorphism (more evident in ISSa) and 
density of the extracellular matrix (more variable in ISSa). The 
inflammatory reaction, characteristic of ISSa, is predominantly 
lymphocytic and characterized by perivascular and perifollicular 
aggregates of lymphocytes and some plasma cells. Another common 
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histologic feature is the presence of large macrophages containing a blue-
gray foreign material within the cytoplasm which has been identified by 
electron probe x-ray microanalysis to be aluminum and oxygen (Hendrick 
et al, 1994; Schultze et al, 1997;  Hendrick et al, 1992). Aluminum hydroxide 
is a common adjuvant in available feline vaccines. These findings would be 
consistent with the presumptive role of inflammation in the pathogenesis 
of ISSa. A morphologic study on 44 primary ISSa  and 10 recurrent tumors 
reported that the most common features in ISSa include the presence of 
peritumoral inflammation, predominantly composed by T cells, abundant 
peripheral vascularity and a prominent myofibroblastic component. The 
presence of multinucleated giant cells was positively correlated to high 
histologic grade tumors and could be indicative of poorly differentiated 
tumors (Couto et al, 2002).  
A study on immunohistochemical marker staining reported that 
most injection site sarcomas are immunoreactive for vimentin and muscle 
markers (desmin, muscle-specific actin HHF35, smooth muscle actin). These 
findings are consistent with a fibroblastic/myofibroblastic phenotype. The 
origin of myofibroblasts is still unclear.  Gabbiani hypothesized that these 
cells are a transitional stage of fibroblasts or macrophages during the 
process of wound healing and therefore considered integral to tissue repair 
(Gabbiani, 1992). The ultrastructural evaluation of feline vaccine associated 
fibrosarcomas by transmission electron microscopy further characterized 
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the cell types within ISSa and confirmed the presence of myofibroblasts, 
giant cells, fibroblastoid cells and histiocyte-like cells (Madewell et al, 2001).  
 
 
1.2.3 Treatment options 
 
The multimodal approach consisting of surgery and pre-operative 
radiotherapy is the best chance for a cure. The median time to first 
recurrence after extensive first surgical excision alone is 325 days whereas 
after marginal excision is 79 days. The median time of first recurrence is 
also related to the location of the tumor. Tumors located on the limbs are 
more suitable to an aggressive wide surgical excision, providing a median 
time of recurrence of 325 days against 66 days for tumors located in other 
sites. Hind limb amputation alone or combined with hemipelvectomy is the 
most successful treatment. However, the long term survival remains low 
with a two-year survival of 13.8% (Hershey et al, 2000). 
Radiation therapy can be used alone as palliative treatment or in 
combination with complete surgical resection for a curative intent. 
Irradiation as a palliative treatment does not improve the survival but it 
allows a more comfort of the patient by reducing the tumor size. Radiation 
therapy in combination with surgery results in improvement of local 
control of the tumor. Cronin et al reported a study of 33 ISSa treated with 
pre-operative irradiation followed by surgery. The median first time 
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recurrence was 398 days and the median survival was 600 days. The only 
variable that influenced the treatment success was the presence of tumor 
cells at the margin of excised tissue after irradiation with a median first 
time recurrence of 112 days for positive margins and 700 days for negative 
margins (Cronin et al, 1998). A larger study conducted at the North Carolina 
State University, USA on 92 ISSa confirmed the completeness of excision as 
only variable influencing the patients‟ outcome, with a median time of first 
event of 986 day for cats having a complete surgical excision and 292 for 
cats with incomplete excision (Kobayashi et al, 2002). 
 The role of chemotherapy in ISSa management has not been fully 
determined. Feline sarcomas are not very chemoresponsive in general. 
However, the effectiveness of several chemotherapeutic agents including 
carboplatin, doxorubicin, liposome-encapsulated doxorubicin, 
mitoxantrone, cyclophosphamide, and vincristine has been investigated in 
the treatment of ISSa. Some partial and complete responses have been 
reported with the use of various chemotherapeutic protocols (Barber et al, 
2000; Couto et al, 1998). Chemotherapy has been used in conjunction with 
radiation therapy as a radiation sensitizer (Cronin et al, 1998) and as pre-
operative setting in order to reduce the size of the tumor and facilitate the 
surgery resection. Chemotherapy alone may be used as palliative treatment 
for large unresectable tumors. A study of 12 cats with non-resectable ISSa 
treated with a protocol of combined doxorubicin and cyclophosphamide 
showed a remarkable improvement of the quality of life and survival in 50% 
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of the treated animals. The median survival time was 242 days for the cats 
that responded to the therapy against 83 days for the non responsive 
(Barber et al, 2000).  
The effects of immunotherapy and novel approaches as a treatment 
option in injection site sarcomas are still under investigation. Some studies 
suggest that Acemannan Immunostimulant could be a valid adjunct to 
surgery and radiation therapy (King et al, 1995). Targeting the PDGF 
receptors with the tyrosine kinase inhibitor imatinib mesylate  (STI-571) 
has been evaluated in vitro and in xenograft model. Imatinib inhibited cell 
proliferation and receptor autophosphorylation (Katayama et al, 2004).  
However, the use of tyrosine kinase inhibitors to block PDFG 
receptor has not been tested in the clinic. A study conducted at North 
Carolina State University, USA evaluated the effect of hyperthermia to 
increase liposome uptake in feline sarcomas. The liposome uptake resulted 
significantly increased in heated tumors (Matteucci et al, 2000). Therefore, 
the use of hyperthermia may be used to improve drug delivery to tumors.  
 Although the best method of treatment of injection site sarcomas 
remains a multimodal approach with pre-operative irradiation and 
aggressive surgery, approximately 25% of cats affected by these tumors 
develop metastasis and only 50% achieve long term control (Hauck, 2003). A 
better understanding  of the molecular pathogenesis and specific cellular 
pathways involved in malignant transformation is important to individuate 
novel and more effective treatment approaches. 
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1.3 Fibroblast Growth Factor Receptors 
 
1.3.1 Fibroblast Growth Factors 
 
Fibroblast Growth Factors (FGFs) family consist of 22 structural 
related polypeptides (Zhang et al, 2006). FGFs  play a key role in a variety of 
physiological processes including embryonic development, angiogenesis, 
wound healing and tissue repair, metabolism and cancer (Naski et al, 1998; 
Kharitonenkov, 2009; Turner et al, 2010).  
Most FGFs contain a  conserved core sequence of 28 highly 
conserved and six identical amino acids. The conserved sequence provide 
FGFs of a common tertiary structure and is responsible of their ligand 
specificity to heparin or heparin sulphate proteoglycans and FGF receptors 
(Ornitz, 2000; Faham et al, 1996). The FGF family has been divided into 
several subfamilies grouped on sequence homologies. However, basing on 
their action mechanisms, three main groups can be identified among the 
FGFs: the intracellular subfamily (FGF 11-14), the hormone-like or 
endocrine subfamily (FGF 19/21/23) and the canonical FGF subfamily 
(Fgf1/2/5, Fgf3/4/6, Fgf7/10/22, Fgf8/17/18, and Fgf9/16/20) (Itoh et al, 
2004; Itoh et al, 2008). Canonical FGFs act as local autocrin-paracrin factors 
by binding and activating FGFRs. Hormon-like FGFs act in a FGFR-
dependent manner as well but have a reduced heparin-binding affinity 
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which allows them to diffuse into the circulation and act as endocrine 
factors.  Intracellular FGFs are intracellular signaling molecules which act 
in a FGFR-independent manner  and are mainly involved in post-natal 
neuronal functions (Itoh, 2010; Goldfarb et al, 2007).  
Most FGFs possess a amino (N)-terminal conventional sequence and 
pass through a secretory pathway which includes the endoplasmic 
reticulum (ER) and Golgi complex (Ornitz et al, 2001). The signal sequence is 
cleaved by peptidases after the protein has crossed the ER membrane 
(Dalbey et al, 2002). In contrast, FGFs -9, -16 and -20 have an uncleaveable N-
terminal and central hydrophobic region which are both crucial  for their 
secretion (Miyakawa et al, 2003). FGF-1 and FGF-2 (also known as acidic and 
basic FGF, respectively) lack the signal peptide and are secreted by a 
mechanism of exocytosis independent of the ER-Golgi pathway (Mignatti et 
al, 1992).  
The interaction between FGFs and  heparin or heparan sulfate 
proteoglycan (HSPG) is an important characteristic of FGF signaling. 
Heparan sulfate (HS) is a group of  linear  polysaccharides located at the 
surface of cells and in the extracellular matrix (ECM). HS chains are usually 
attached to core proteins, forming a class of glycoproteins called 
proteoglycans (Bernfield et al, 1999). The interaction between secreted FGFs 
and HS in the ECM seems to have the dual function to restrict the diffusion 
and release of FGFs into the interstitial spaces, and to protect FGFs from 
degradation (Ornitz et al, 2001; Sasisekharan et al, 1997). To signal, FGFs 
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must saturate nearby HS-binding sites or be released from the extra-
cellular matrix (ECM) by heparin/ HS-degrading enzymes. HSPGs on cell 
membrane are essential to facilitate the binding of FGFs with the fibroblast 
growth factor receptors (FGFRs) by the formation of Heparin/HS – FGF – 
FGFR trimolecular complex (Schlessinger et al, 2000). Several studies also 
indicated that HS also provide an additional level of selectivity to the FGF 
signaling, determining which FGFs bind and activate FGFRs (Rahmoune et 
al, 1998; Powell et al, 2002; Kan et al, 1999) 
 
1.3.2 Fibroblast growth factor receptors 
 
To date, 5 FGF receptors (FGFRs) have been identified and named 
FGFR1, FGFR2, FGFR3, FGFR4 and FGFR5. FGFRs belong to the family of 
tyrosine kinase receptors which show a conserved structure composed by a 
signal peptide, an acidic box, a ligand binding extracellular domain, a single 
transmembrane helix and an intracellular portion containing the kinase 
domain. The extracellular domain consists of three immunoglobulin (Ig) 
like domains (IgI, IgII and IgIII). FGFR5 (also known as FGFRL1) lacks a 
cytoplasmic tyrosine kinase domain and might negatively regulate FGF 
signaling (Wiedemann et al, 2000; Sleeman et al, 2001; Steinberg et al, 2010). 
The receptors‟ ligand specificity is located at IgII and IgIII domains. IgII 
domain contains a highly conserved region that serves as a binding site for 
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heparin whereas IgIII is responsible of the FGF ligand binding specifity 
(Schlessinger et al, 2000).   
The fgfr1-4 genes consist of up to 20 exons which encode for a highly 
conserved protein structure among different species (Rebscher et al, 2009; 
Zhang et al, 1999).  
Several isoforms for FGFR1-3 derive from alternative splicing of 
mRNAs including variable exons. The role of IgI domain is still 
controversial. The IgI domain and can be removed by exon skipping 
resulting in FGFRs which maintain the ability to bind ligands and transmit 
signaling. Thus, the IgI domain would be not essential in the receptor 
function (Mohammadi et al, 2005). Other studies showed that the deletion of 
IgI domain in FGFR1 originates a oncogenic receptor variant in glial cell 
tumors (Jin et al, 1999; Jin et al, 2000). Particularly important is the 
alternative splicing of the second half of the IgIII domain. Indeed, the splice 
event at the C-terminal part of IgIII yelds the IgIIIb or IgIIIc receptor 
isoforms which have distinct ligand binding specificities. The FGFR4 is not 
alternatively spliced and expresses a single IgIII isoform. Interestingly the 
splicing event for FGFR1-3 occurs in a tissue-specific manner with the IIIb 
isoform expressed in epithelial cells and IIIc expressed in mesenchymal 
cells (Orr-Urtreger et al, 1993; Ornitz et al, 2001; Johnson et al, 1993). This 
expression pattern seems to be less specific for FGFR3 IIIc isoform which 
can be found in both epithelial and mesenchimal tissues (Scotet et al, 1995). 
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1.3.3 FGFR signaling pathways 
 
Like other tyrosine kinases receptors, Fibroblast Grwoth Factor 
Receptors transmit extracellular signals to several intracellular 
transduction pathways through tyrosine phosphorilation. The binding of 
FGF and HPSP to the extracellular Ig-like domains induces receptor 
dimerization, activation and autophosphorylation of  multiple intracellular 
tyrosine residues (Lemmon et al, 1994). The phosphorylation of tyrosine 
residues, in turn, is responsible of the recruitment of other signaling 
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molecules to the receptor cytoplasmic tail leading to a variety of 
transduction pathways (Pawson, 1995).  
Various signalings can originate from the activation of FGFRs 
including  phospholipase C gamma (PLCγ), Crk, SNT-1/FRS2, Ras/Mitogen-
activated protein kinase (MAPK) cascade and the Phosphoinositide Kinase-3 
(PI3K) pathways (Kan et al, 1999).  
Activated PLCγ cleaves phosphatidyl-inositol-4,5-bisphosphate to 
inositol trisphosphate (IP3) and diacylglycerol (DAG). In turn, IP3 induces 
the release of calcium deposits from the endoplasmic reticulum, while DAG 
and calcium activate Protein kinase C (PKC). Several studies evaluated the 
effects on mutation of the tyrosine residue Tyr766 of FGFR1 which is 
involved in the activation of PLCγ. FGFR-mediated mitogenesis and 
differentiation was not affected by mutation of  Tyr766 (37,38). Thus, PLCγ  
signaling may be either redundant or important for other functions of FGFR 
signaling (Powers et al, 2000). Despite not directly involved in cell motility, 
the PLCγ pathway may be involved in cytoskeletal alterations as the actin-
binding protein profillin participates in this signaling pathway 
(Goldschmidt-Clermont et al, 1991). 
 Crk is an adaptor protein which link FGFR to the signaling 
molecules Shc, C3G and Cas. The Crk signaling pathway transduce a 
mitogenic signal from FGFRs (Larsson et al, 1999).  
A 90-kDa protein was independently identified by two separate 
groups and called Suc1-associated neurotrophic factor target (SNT-1) or 
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Fibroblast growth factor receptor substrate-2 (FRS2) (Wang et al, 1996; 
Kouhara et al, 1997). The SNT-1/FRS2 protein linked FGFR activation to the 
Ras/MAPK signaling pathway which is important for cell-cycle progression 
mediated by growth factors. Upon phosphorylation resulting from FGFR 
activation, FRS2 forms a complex with growth factor receptor-bound 2 
(Grb2) both directly by its own Grb2 binding domains and indirectly via 
Shp2 (Hadari et al, 2001). Through Grb2, the FRS2 signaling complex 
recruits the guanine nucleotide exchange factor SOS (son of sevenless), 
which activates Ras and the downstream RAF and MAPK pathways 
including the ERK, p38 and JNK1/2 pathways (Eswarakumar et al, 2005).  
Phosphorilation of FRS2 is also involved in the activation of the PI3K 
pathway through the formation of Grb2-mediated complex with the 
docking protein Gab1 (Ong et al, 2001). The interaction and coordination of 
FRS2 with several docking proteins show the central role of FRS2 in FGF 
transduction.  
Various additional factors such as Shb (src homology 2 domain–
containing transforming protein B), Src kinase, RSK (ribosomal S6 protein 
kinase) and STATs (signal transducers and activators of transcription) have 
also been implicated in promoting FGF-mediated signaling. 
Attenuation and negative regulation of FGFR signaling is important 
for maintaining the normal function of the FGF signaling pathway. 
Attenuation is mainly mediated by FGFR endocytosis followed by lysosomal 
degradation of the receptor (Haugsten et al, 2008). Several proteins 
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including the MAPK phosphatase 3 (MKP3), the Sprouty proteins, and Sef 
(similar expression to FGF) family members play also a role in the 
attenuation of FGFR signaling (Turner et al, 2010; Haugsten et al, 2010).  
 The activation of particular signaling pathways produces various 
cellular responses  including differentiation, proliferation, growth arrest 
and apoptosis (Dailey et al, 2005). Among the MAPK pathways, the ERK1/2 
kinases are responsible of mitogenic resposes; JNK are important in 
controlling programmed cell death or apoptosis and p38 is usually 
associated with inflammatory responses (Johnson et al, 2002). Recent 
studies showed that the FGF-FGFRs signaling must be considered a „context 
dependent signaling‟ where each signaling pathway can yield to differential 
cellular responses depending on several factors including cell-type, cellular 
differentiation stage, magnitude and duration of FGF stimulation (Turner et 
al, 2010; Jacob et al, 2006; Garcia-Maya et al, 2006). 
 
1.3.4 FGF-FGFR signaling in cancer 
 
Aberrant FGF signaling is related to the pathogenesis of a variety of 
cancers by different mechanisms including activating mutations, 
chromosomal rearrangements, upregulation,  fusion proteins, availability 
of ligands and impaired termination consequent to defective negative 
regulation system. 
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There is large evidence showing presence of activating mutations of 
fgfr genes in human cancer. FGFR3 activating mutations have been 
identified in cervical cancers, multiple myeloma, prostate cancer and 
spermatocytic seminomas. Somatic mutations of FGFR3 coding sequence 
have been found in  approximately 50% of bladder cancers and usually 
involve a single position in the extracellular domain of the receptor which 
is responsible of constitutive dimerization and receptor activation. 
Mutations of FGFR2 have been reported in 12% of endometrial carcinomas. 
The high sensitivity of endometrial cancer cells to FGFR tyrosine kinase 
inhibitors confirms the role of this receptor in oncogenesis (Turner et al, 
2010). 
Fgfr gene amplification is another mechanism involved in 
tumorigenesis. FGFR2 amplification has been reported in 10% of gastric 
cancers and is associated with poor prognosis. Amplification of FGFR1 
occurs oral squamous carcinoma, ovarian cancer, bladder cancer and 
rhabdomyosarcoma. Upregulation of the chromosomal region 8p11-12 
which is the location of FGFR1 has been reported in 10% of breast cancers; 
however, this region is gene rich and FGFR1 is not always amplified. 
Amplification of FGFR1 is frequent in human prostate cancer. A study 
conducted on a mouse model showed that conditional activation of FGFR1 
in prostate epithelial cells leads to epithelial to mesenchimal transition 
(EMT) and adenocarcinoma induction (Acevedo et al, 2007). In the EMT 
epithelial cells are converted into mesenchymal cells which possess 
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migratory properties and consequent invasiviness in epithelial tumors. This 
study also reported that regression was achieved by early inhibition of 
FGFR1 whereas late inhibition induced reduction of proliferation but  not 
regression. 
 
1.3.5 Exon switching in cancer 
 
Exon switching between alternatively spliced variants is involved in 
tumor growth and progression (Itoh et al, 1994; Cha et al, 2009). The ligand 
binding specifity is determined by the second half of the third Ig-like 
domain. Thus, the alternative splicing of this domain generating the IIIb 
and IIIc splice variants is crucial to control the FGF signaling. As mentioned 
above, the IIIb isoforms are expressed in epithelial cells, whereas the IIIc 
isoforms are usually expressed in mesenchymal cells. The expression of 
FGFs also appears tissue-specific with the ligands for IIIb splice variants 
expressed in mesenchymal cells and the ligands for IIIc splice variants 
expressed in epithelial cells. This particular expression pattern implies that 
FGFR signaling acts in a paracrine manner between epithelial and 
mesenchymal cells. The exon switching and the consequent switching of 
the expressed isoform leads in contrast to autocrine signal.  
Most studies on the relation between exon switching and cancer 
have been conducted on FGFR2 in epithelial tumors. In rat models, swithing 
from FGFR2 IIIb to IIIc isoforms has been described in bladder and prostate 
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cancer. The switch resulted in altered FGFR signaling, autocrine activation 
of FGFR2, aberrant signaling balance between epithelial and mesenchymal 
cells and led to epithelial to mesenchymal transition (Savagner  et al, 1994; 
Oltean et al, 2006). The re-expression of the FGFR2 IIIb isoform in rat and 
human prostate and bladder cancer cell lines resulted in growth 
suppression in vitro and in reduced tumor formation in vivo (Matsubara  et 
al, 1998; Yasumoto et al, 2004).  
Downregulation of IIIb and IIIc isoforms has also been described in a 
variety of human cancers and suggested that FGFR2 may act as tumor 
suppressor (Takeda et al, 2007). A study conducted by  Grose et al in mutant 
mice showed that FGFR2 IIIb possesses a tumor-protective role in 
keratinocytes by preventing them from the development of papillomas and 
carcinomas which was instead noticed in mice with a FGFR2 IIIb delection 
in keratinocytes (Grose et al, 2007).   
Althogh extensive research investigated the role of FGFR signaling 
in epithelial tumors, very little is known about its role in sarcomas.  A study 
conducted on both human and canine  soft tissue sarcomas reported that 
all FGFRs and their splice variants can be identified in these tumors, with 
FGFR1 IIIc isoform having the highest transcription levels (Holzmann et al, 
2011). 
Exogenous and endogenous factors are involved in the choice of the 
alternative exons that leads to the transcription and expression of the IIIb 
vs IIIc isoforms. Among the exogenous factors the alterations that lead to 
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EMT in tumors such as snail genes activation, loss of E-cadherin and 
upregulation of the WNT pathway seem to be related to the splice 
regulation. However, it is not clear if the splice choice is a cause or effect of 
EMT (Holzmann et al, 2011). FGF-signaling itself may be responsible of the 
exon swithching (Yan et al, 1993; Scotet et al, 1998). Understanding 
alternative splicing regulation at the transcriptional level is a complex 
research field. The regulation seems to be specific to cell type, 
developmental stage and signalling pathway. In the recent years particular 
importance has been given to the cis and trans components, which are 
composed of sequences in the pre-mRNA and cellular factors (RNA or 
protein), respectively, and interact with splicing silencer and enhancer 
proteins (Matlin et al, 2005;  Hanamura et al, 1998).  
 
1.3.6 FGFR as target in tumor treatment 
 
Fibroblast growth factor signaling is one of the major focuses for the 
development of new targeted therapies in several types of cancer. 
Extensive research is currently being conducted to identify and test 
compounds that could be suitable for therapeutic use. 
In the recent years several FGFR tyrosine kinase inhibitors (TKIs) 
have been developed and are currently in the early phase of clinical trials. 
Current TKIs targeting FGFRs frequently are also active against vascular 
endothelial frowth factor receptor 2 (VeGFR2) and/or platelet-derived 
  
Viviana Le Donne. “Relative expression of fibroblast growth factor receptors in feline sarcomas”. Tesi di 
dottorato in Riproduzione, produzione e benessere animale. Università degli Studi di Sassari.    
                                                                                                                                                           32 
 
growth factor receptor (PDGFR) which share a high structural similarity 
with FGFRs (Turner et al, 2010; Heinzle et al, 2011). Many pharmaceutical 
companies are developing TKIs specific for FGFRs to avoid a potential 
increase of the effects due to multiple receptors targeting compounds. 
However, preclinical development of these drugs has often been 
complicated by side effects in vitro and in vivo models. Potent FGFR 
tyrosine kinase inhibitors seem to block the FGF23 signaling which is 
involved in phosphate hemostasis and lead to hyperphosphatemia and 
consequent tissue calcification (Shimada et al, 2004; Turner et al, 2010). A 
new potent and selective TK inhibitor of the fibroblast growth factor 
receptors 1-3 has been recently identified. The compound showed a 
significant antitumor activity in vitro and in bladder cancer xenografts 
models which overexpressed wild-type FGFR3 (Guagnano et al, 2011). 
Therapeutic antibodies against specific FGFRs are also under 
investigation. One of the potential benefices of this therapeutic approach is 
the minimization of the side effects and toxicity of non-specific FGFR TKIs. 
Anti-FGFR3 antibodies have an antiproliferative effect on bladder cancer 
cells (Martinez-Torrecuadrada et al, 2005; Qing et al, 2009) and t(4;14)-
positive myeloma (Qing et al, 2009). A single chain Fv antibody targeting the 
FGFR1 IIIc has been reported to cause severe hypophagia and weight loss in 
rodents and monkey models consequent to a potential block of the FGF 
signaling in the hypothalamus (Sun et al, 2007).  
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In 2007 a study was conducted to evaluate a soluble FGFR1 receptor 
antagonist (FP-1039) which showed inhibition of tumor growth and 
angiogenesis. This fusion protein consists of FGFR1IIIc fused to the Fc 
domain of IgG1 and may play a role in blocking the activity of FGF ligands 
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2. Aims of the present study 
 
The present study aimed to determine whether the fibroblast 
growth factor receptors 1-4 are expressed in feline  injection site sarcomas 
and non-injection site sarcomas and whether the receptors' expression is 
differential in ISSa if compared to non-ISSa. The specific aims were as 
follows: 
 
 To amplify, by standard PCR, and sequence the exons of the fgfr1-4 
genes using normal feline tissue (liver). 
 
 To assess, by qRT-PCR, the presence and the expression levels of 
mRNA for the FGFR1-4 and their splice variants IIIb and IIIc on 
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3. Materials and methods 
 
The experiment was conducted at Dr. Marlene Hauck‟s Laboratory, 
Department of Clinical Sciences – College of Veterinary Medicine - North 
Carolina State University, 4700 Hillsborough Street, Raleigh NC 27606. 
 
 
3.1 Genomic DNA sequencing 
 
3.1.1 Samples and DNA extraction 
 
Normal feline liver biopsies were used in this study. Samples were 
stored in RNA later solution  (Invitrogen - Carlsbad, California, USA) at -
80°C. Total genomic DNA was extracted by using the QIAGEN DNAeasy 
Blood and Tissue mini-kit according to manufacturer‟s instructions (Qiagen 
- Valencia, CA, USA). NanoDrop 1000 Spectrophotometer (Thermo 
Scientific) was used to determine double-stranded (ds) DNA concentration 
(ng/uL) and purity. ds-DNA purity was determined by the ratio of sample 
absorbance at 260 and 280 nm and the ratio of sample absorbance at 260 
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3.1.2 Primers designing 
 
Sense and antisense oligonucleotide primers were designed based on 
the predicted sequences published on Ensembl database (accession 
numbers: ENSFCAG00000013612, ENSFCAG00000003692, 
ENSFCAG00000018385, ENSFCAG00000016224) and are reported in tables 
3.1-4. Primer pairs were designed by the Primer3 software (v.0.4.0) 
(SourceFourge) on the intronic sequences before and after each exon. 
Human and canine sequences alignments (Clone Manager software) were 
used to design primers when the intronic sequence was unknown. Each 
primer pair was checked for specificity (Primer-BLAST - NCBI) and primer-
dimers  (Oligo Analysis Tool by MWG Operon-Eurofins). All primers were 
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Table 3.1: Primers used to sequence FGFR1 exons with their flanking 
intronic sequences 
Target  Forward primer 5’-3’ Reverse primer 5’-3’ Product 
size 
Exon 1 AATTCAGTATTGGGGCAGGA CCTTCCCAGTCAACCACAAC 440 bp 
Exon 2 CTTCCTGTCCCATCCCTTG CTCCCCCTGAAACTAGCAGA 392 bp 
Exon 3 GCTGGCTGTTGATATGGAT TCATCTAAGCCTCCCCCTTC 242 bp 
Exon 4 ACTAGCCCCTGCCTGTCTCT GCCCCCAGACTGAAAAGATT 391 bp 
Exon 5 TCCATTTTCCTCCAGACTCG TCCTTAACCTTGTTGCCACTG 203 bp 
Exon 6 AGCCTCTCCTCTCCCTTCCT AGCCTGACCACAGCAACTG 298 bp 
Exon 7 (IIIb) CGTCTCACTCGCCTTAGCTC ATACAGCAGGATAACAGGGAGAG 367 bp 
Exon 8 (IIIc) GCGTCTGGTGAAGGGTTGTA CCTGCAAAACGAGGACAGAT 575 bp 
Exon 9 GAAAGGAGATGGGGGTTGTT AGGACATTCCACTGCCTCTG 447 bp 
Exons 10-11 GTTGGTGGAAAGCCCTAAG TTGCAGGGACAGAAACATCA 587 bp 
Exon 12 AGGGAGGAGAGAAGCCAGTC CTCACTGATACCCCCAGCTC 351 bp 
Exon 13 CAGTTGGGGGTGGGGTTT CACAGAAAAGGGGCAGTGT 498 bp 
Exon 14-15 ATCCCACCTCATCTCTGCAC CAGACTGGCCTTTCAACCTC 595 bp 
Exon 16 AAAGGCCAGTCTGTTCTCCA CAGGATTGTTGAGTCAGGGG 476 bp 
Exons 17-18 GGTAGATCAAGTAGCCCT TTGCGAGGAGGAGGAAGA 671 bp 
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Table 3.2: Primers used to sequence FGFR2 exons with their flanking 
intronic sequences. No valid primers were found for exons 1,3-4,7-9 
Target Forward primer 5’-3’ Reverse primer 5’-3’ Product 
size 
Exon 2 GCCCTACAGCTTGTGGAGAC TTCACCCAGAAAACGGCTAC 574 bp 
Exon 5 CCACCTTTCCTTTGATCTTT ACGTCCATTTCACCCAAAAC 411 bp 
Exon 6 CTTTTTGGCTTGCGTTCAC GCTCATTCCCGAAACACACT 445 bp 
Exon 10 TCAGGTGGAGCCAGGATTAC GAACCATTTCAGCCCCATATT 678 bp 
Exon 11 ACCAGATGCCGTGTGCTAAT AAGACTTTCCACCCCTTTCC 211 bp 
Exon 12 GCTGACGGGTTAAGAGACA ACGGTCACAAAGTCGCCT 349 bp 
Exon 13 TCTCGAAAGCAGTTCCCAGT AGCCCCTGTGTGAATAATGC 625 bp 
Exon 14 TGATGTATTTCCTCTCTGCA GCTCGCTCTCTCTCAAAAA 372 bp 
Exon 15 GCTCTTCAGTGAGGCACA ATTCGATAGCGGCTTTGAG 457 bp 
Exon 16 GTTGAGGGTTTTTGCGATTC TGGCTGTCAGTGTGGCTATC 383 bp 
Exon 17 GTAAAACCCGAAGCGTGAGA CGTGAGTCCGCTCTGAGAA 426 bp 
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Table 3.3: Primers used to sequence FGFR3 exons with their flanking 
intronic sequences. No valid primers were found for exons 2-7, 11-12 
Target Forward primer 5’-3’ Reverse primer 5’-3’ Product 
size 
Exon 1 GCCCTTACGCATGTTCTGAT TCCCCGTCTTCGTCATCTCC 758 bp 
Exon 8 GCTGGTGTGGGGATAAAGTG GGAGGGGGCATCTGACTT 789 bp 
Exon 9 CTTCCTTCGTGTAGGGCTGA GCCTCCTCTGGTCGATAGT 481 bp 




Table 3.4: Primers used to sequence FGFR4 exons with their flanking 
intronic sequences.  
Target Forward primer 5’-3’ Reverse primer 5’-3’ Produ
ct size 
Exons 1-7 CGGCTGTGTGTGTGTATGTG TGCTGGAGGTCAAGGAGTCT 808 bp 
Exon 8-10 GAGAGAGATCCTCCCCATCC CTTCCCACTTCCCACAGAAA 650 bp 
Exon 11 TCATGGACACTTCCCCTGT GGCAGCTTGAGCCATCTAAG 261 bp 
   Exon 12-
17 
GCAACATGGACTTGGTCTT GGTGCCTAACCCCAGTCAT 1940 bp 
Exons 18-
19 
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3.1.3 Standard Polymerase Chain Reaction (PCR) 
 
Polymerase chain reaction was performed using a commercially 
available Taq polymerase (Qiagen, Valencia, CA, USA ). PCR protocol is 
described in Table 3.5. The thermal profile consisted of predenaturation at 
94˚C for 3 minutes, 32 cycles of denaturation at 94˚ for 30 seconds, 
annealing step at variable temperatures (range between 5 and 3 degrees 
under the primer‟s melting temperature) for 30 seconds, extension step at 
72˚C for 1 minute and a final extension step at 72˚C for 10 minutes. PCR 
products were  electrophorezed in 2% TAE-agarose gel and stained for 20 
min in a TAE solution supplemented with 1X ethidium bromide. DNA was 
visualized under UV illumination. PCR products of the expected size were 
column-purified using the QIAquick PCR Purification Kit (Qiagen) according 
to the manufacturer's instructions, and eluted in 15 μl of nuclease free 
distillated water. DNA sequencing reactions were performed by an external 
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Table 3.5: Regular PCR protocol 
Reagent Final concentration 
10X PCR buffer 1X 
dNTP 200 µM each dNTP 
Forward primer 0.4 µM 
Reverse primer 0.4 µM 
Taq Polymerase 2.5 units/reaction 
Template dsDNA 50 ng 
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3.2  Relative expression of Fibroblast 
 growth factor receptors 
 
3.2.1 Cell cultures 
 
Four feline injection site sarcomas (Ela, Hamilton, Rose and Tietz) 
and two non-injection site sarcomas (Kaiser and Molly) cell lines were used 
in this study. All cells were cultured in identical conditions in media 
containing DMEM (Mediatech) supplemented with 10% FBS (Mediatech) and 
1X peni-streptomycin. Cells were grown at 37°C in 5% CO2 and atmospheric 
O2. Total RNA was extracted and treated by DNAse from 80% confluent cells 
using the RNeasy mini kit (Qiagen) according to the manufacturer‟s 
instruction. NanoDrop 1000 Spectrophotometer (Thermo Scientific) was 
used to determine RNA concentration (ng/uL) and purity. Purity was 
determined by the ratio of sample absorbance at 260 and 280 nm and the 
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Figure 2: Ela-ISSa (20X) 
 
 
Figure 4: Hamilton-ISSa (20X) 
 




Figure 5: Kaiser non-ISSa (20X)
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3.2.2 Frozen tumor samples 
 
Five feline injection site sarcomas (Ashley, Bianca, Suki, Candace and 
Tigger) and three non-injection site sarcomas (Alice, Gabriel and Phantom) 
tumor samples stored in RNA-later (Invitrogen) at -80°C were used in this 
study. Total RNA was extracted and treated by DNAse using the RNeasy 
mini kit (Qiagen) according to the manufacturer‟s instruction. NanoDrop 
1000 Spectrophotometer (Thermo Scientific) was used to determine RNA 
concentration (ng/uL) and purity. Purity was determined by the ratio of 
sample absorbance at 260 and 280 nm and the ratio of sample absorbance at 
260 and 230 nm.  
 
3.2.3 Formalin-Fixed  Paraffin-Embedded (FFPE) samples 
 
A total of 408 FFPE samples collected from 1998 to 2011 at the Small 
Animal Hospital of the College of Veterinary Medicine – North Carolina 
University were considered in this study. Samples with incomplete or 
absent history, previous radiation therapy treatment, no histopathology 
report were excluded from this study.  54 FFPE samples were finally 
included in the project and consisted of 41 injection-site sarcomas and 13 
non-injection site sarcomas. All samples were deparaffinized by the Qiagen 
Deparaffinization solution. RNA extraction was performed using the RNeasy 
FFPE kit (Qiagen) according to the manufacturer‟s instructions. NanoDrop 
1000 Spectrophotometer (Thermo Scientific) was used to determine RNA 
  
Viviana Le Donne. “Relative expression of fibroblast growth factor receptors in feline sarcomas”. Tesi di 
dottorato in Riproduzione, produzione e benessere animale. Università degli Studi di Sassari.    
                                                                                                                                                           46 
 
concentration (ng/uL) and purity. Purity was determined by the ratio of 
sample absorbance at 260 and 280 nm and the ratio of sample absorbance at 
260 and 230 nm. The assessment of RNA integrity was determined by 
evaluation of the RNA Integrity Number (RIN) using the Agilent 2100 
bioanalyzer and RNA LabChip® kits (Agilent).  3 non-ISSa and 2 ISSa samples 
had a RIN < 1.4 and were excluded from the q-RT-PCR gene expression 
analysis (Ribeiro-Silva A. et al, 2007). Gene expression was therefore 
evaluated in 39 ISSa and 10 non-ISSa FFPE samples. 
 
3.2.4 RNA to cDNA conversion 
 
The RNA extracted from all cell lines, frozen tumor samples and 
FFPE samples was converted into cDNA using the QuantiTect Reverse 
Transcription Kit (Qiagen). 
 
 
3.2.5 Primers designing 
 
Sense and antisense oligonucleotide primers for FGFR1 IIIb-IIIc 
splice variants and FGFR4 were designed based on the exonic sequences 
obtained from the genomic DNA sequencing. For FGFR2 IIIb-IIIc isoforms 
and FGFR3 IIIb-IIIc isoforms, primers were designed based on the respective 
human mRNA sequences (Ensembl accession numbers: ENST00000457416, 
ENST00000358487, ENST00000340107, ENST0000026079). q-RT-PCR primers 
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are reported in table 3.6. Primer pairs were designed by the Primer3 
software (v.0.4.0) (SourceFourge). Each primer pair was checked for 
specificity (Primer-BLAST - NCBI) and primer-dimers  (Oligo Analysis Tool 
by MWG Operon-Eurofins). All primers were ordered from Invitrogen 
(Carlsbad, California, USA). The amplification efficiency of each primer pair 
was determined by serial dilution experiments, and the resulting efficiency 


















Viviana Le Donne. “Relative expression of fibroblast growth factor receptors in feline sarcomas”. Tesi di 
dottorato in Riproduzione, produzione e benessere animale. Università degli Studi di Sassari.    
                                                                                                                                                           48 
 
Table 3.6: q-RT-PCR primers  





CCCCATATCCAGTGGCTAAA ACACACATACTCCCCGCTCT 1.18 
FGFR1 
IIIc 
CCCCATATCCAGTGGCTAAA ATAGAGTTACCCGCCAAGCA 1.17 
FGFR2 
IIIb 
GACGGGCTACCCTACCTCA GCAAGCACTTCTGCATTGG 0.98 
FGFR2 
IIIc 
GTGCTTGGCGGGTAATTCTA CAGGTAGTCTGGGGAAGCTG 0.96 
FGFR3 
IIIb 
ACATCCAGTGGCTCAAGCA GTCCCGCTCCGACACATT 1.09 
FGFR3 
IIIc 
CACAACGTCACCTTTGAGGA CCACGCAGAGTGATGAGAAA 1.15 
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3.2.6  Real Time Quantitative  Reverse Transcription Polymerase Chain Reaction (q-
RT-PCR) 
 
Comparative real time-PCR was done using a SYBR green detection 
system (Step-one Applied Biosistems). 1 µL (50 ng)  of cDNA template, 0.4 µL 
(10 µM) of forward and reverse primers, 8.2 µL of nuclease free water and 
10 µL of SybrGreen Mix in a total volume of 20 µL were applied to the 
following conditions: denaturation and Taq activation at 95°C for 10 
minutes; amplification for 40 cycles at 95°C for 15 seconds and 60°C for 1 
minute. All reactions were run in triplicate or duplicate depending on the 
available amount of starting template and a no-template control was 
included in each qRT-PCR experiment. Three feline housekeeping genes, 
ribosomal protein L17 (RPL17), tryptophan 5'-monooxygenase activation 
protein zeta isoform (YWHAZ) and peptidylprolyl isomerase A (PPIA) 
(Penning et al, 2007), were used as control genes. The qRT-PCR reaction was 
evaluated by melting curve analysis. 
Quantitation of mRNA levels was obtained by the Pfaffl  method 
(Pfaffl, 2001). Relative quantification of gene expression was achieved by 




2.2.7 Statistical analysis of gene expression data 
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Statistical analysis of the relative expression levels of FGFR1-3 IIIb-
IIIc and FGFR4 in injection site sarcoma compared to non-injection site 
sarcoma samples was first performed for each sample type (cell lines, 
frozen tumor samples and FFPE) and finally between all ISSa vs all non-ISSa 
samples using the relative expression software tool (REST) (Pfaffl et al, 
2002). The REST software uses randomisation tests with a pair-wise fixed 
reallocation as statistical model. Differences with P<0.05 were considered 
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4.1   Genomic DNA sequencing 
 
Genomic nucleotide sequencing was successfully performed for all the 18 
exons of FGFR1; exons 2, 5, 6, 10-18 of FGFR2; exons 1, 8-10 of FGFR3 and  all 
the 19 exons of FGFR4. The nucleotide sequences of each exons and their 
alignment with human and canine sequences for FGFR1-3 are reported in 
tables 4.1-3. The sequencing of the feline FGFR4 gene confirmed the 
predicted sequence published on Ensembl database (accession number 
ENSFCAG00000016224) and completes the unknown regions for exons12-16. 
However, the number, length and arrangement of the FGFR4 exons appear 
different from the respective human and canine gene. The exonic 
sequences of feline FGFR4 with their intronic flanking regions obtained in 
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FGFR1 Exon 1 
feline     ATGTGGAGCTGGAAGTACCTCCTCTTG---GCTGTGCTGGTCACAGCCACGCTCTGCACT 
canine     ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTGTGCACT 
human      ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACC 
           ****************.*********    ********************.** *****  
 
feline     GCCAGGCCAGCCCCGACCTTGCCCGAACAAG 
canine     GCCAGGCCGGCCCCGACCTTGCCTGAACAAG 
human      GCTAGGCCGTCCCCGACCTTGCCTGAACAAG 
           ** *****. ************* ******* 
 
FGFR1 Exon 2 
human     CCCAGCCCTGGGGAGCCCCTGTGGAAGTGGAGTCCTTCCTGGTCCACCCCGGTGACCTGC 
canine    CCCAGTCCTGGGGAGCCCCTGTGGAAGTGGAGTCCTTCCTGGTCCACCCTGGTGACCTGC 
feline    CCCAGCCCTGGGGAGCCCCTGTGGAAGTGGAGTCCTTCCTGGTCCACCCTGGTGACCTGC 
          ***** ******************************************* ********** 
 
human     TGCAGCTTCGCTGTCGGCTGCGGGACGATGTGCAGAGCATCAACTGGCTGCGGGACGGGG 
canine    TGCAGCTTCGCTGTCGGCTGCGGGACGATGTGCAGAGCATCAACTGGCTGCGGGACGGGG 
feline    TACAGCTTCGCTGTCGGCTGCGGGAG-ATGTCCAGAGCATCAACTGGCTGCGGGACGGGG 
          *.***********************  **** **************************** 
 
human     TGCAGCTGGCGGAAAGCAACCGCACCCGCATCACAGGGGAGGAGGTGGAGGTGCAGGACT 
canine    TGCAGCTGGTGGAGAGCAACCGTACCCGCATCACGGGGGAGGAGGTGGAGGTGCGGGATT 
feline    TGCAGCTGGTGGAGAGCAACCGTACCCGCATCACAGGGGAGGAGGTGGAGGTGCGGGACT 
          ********* ***.******** ***********.*******************.*** * 
 
human     CCGTGCCCGCAGACTCCGGCCTCTATGCTTGCGTAACCAGCAGCCCCTCGGGCAGTGACA 
canine     CCGTGCCTGCTGACTCCGGCCTCTACGCTTGTGTGACCAGCAGTCCCTCGGGCAGTGACA 
feline     CGGTGCCTGCCGACTCCGGCCTCTACGCTTGCGTGACCAGCAGCCCCTCGGGCAGCGACA 
           * ***** ** ************** ***** **.******** *********** **** 
 
human      CCACCTACTTCTCCGTCAATGTTTCAG- 
canine     CCACCTACTTCTCCGTCAATGTCTCAG- 
feline     CCACCTACTTCTCCGTCAATGTCTCAGG 
          ********************** **** 
FGFR1 Exon 3 
feline     ATGCTCTCCCCTCCTCGGAGGATGACGACGATGATGATGACTCCTCTTCAGAGGAGAAAG 
human      ATGCTCTCCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAG 
canine     ATGCTCTCCCCTCCTCAGAGGACGACGATGATGATGATGACTCCTCTTCAGAGGAGAAAG 
           ****************.***** ** ** ******************************* 
 
feline     AGACAGATAACACCAAACCAAACCGTATGC 
human     AAACAGATAACACCAAACCAAACC------ 
canine     AGACAGATAACACCAAACCAAACCGTATGC 
           *.**********************       
 
Table 4.1: Feline FGFR1 exons – alignment with human and canine sequences 
  
Viviana Le Donne. “Relative expression of fibroblast growth factor receptors in feline sarcomas”. Tesi di 
dottorato in Riproduzione, produzione e benessere animale. Università degli Studi di Sassari.    


























FGFR1 Exon 4 
 
human           CCGTAGCTCCATATTGGACATCCCCAGAAAAGATGGAAAAGAAATTGCATGCAGTGCCGG 
canine          CCGTGGCTCCGTACTGGACATCCCCAGAAAAGATGGAAAAGAAATTGCACGCGGTGCCGG 
feline         CCGTGGCTCCATACTGGACATCCCCAGAAAAGATGGAAAAGAAATTGCACGCGGTGCCAG 
                ****.*****.** *********************************** **.*****.* 
 
human           CTGCCAAGACAGTGAAGTTCAAATGCCCTTCCAGTGGGACCCCAAACCCCACACTGCGCT 
canine          CTGCCAAGACCGTGAAGTTCAAATGCCCTTCCAGTGGGACTCCCAACCCCACGCTGCGCT 
feline          CTGCCAAGACTGTGAAGTTCAAATGTCCTTCTAGTGGGACTCCTAACCCCACGCTGCGCT 
                ********** ************** ***** ******** ** ********.******* 
 
human           GGTTGAAAAATGGCAAAGAATTCAAACCTGACCACAGAATTGGAGGCTACAAG 
canine          GGTTGAAAAATGGCAAAGAATTCAAACCTGACCACAGGATTGGAGGCTATAAG 
feline          GGTTGAAAAACGGCAAAGAATTCAAACCTGACCACAGGATTGGAGGCTATAAG 
               ********** **************************.*********** *** 
 
 
FGFR1 Exon 5 
 
feline          GTCCGTTACGCCACCTGGAGCATCATAATGGACTCCGTAGTGCCTTCTGATAAGGGCAAC 
canine          GTCCGTTACGCCACCTGGAGCATCATAATGGACTCCGTGGTGCCTTCTGATAAGGGCAAC 
human           GTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTGGTGCCCTCTGACAAGGGCAAC 
                ******** ************************** **.***** ***** ********* 
 
feline          TACACCTGCATTGTGGAGAATGAGTATGGCAGCATTAACCACACCTACCAGCTCGACGTC 
canine         TACACCTGCATTGTGGAGAACGAATATGGCAGCATTAACCACACCTACCAGCTCGATGTC 
human           TACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAACCACACATACCAGCTGGATGTC 
                ******************** **.** ******** ********.******** ** *** 
 
feline          GTGG 
canine          GTGG 
human           GTGG 
                **** 
 
 
FGFR1 Exon 6 
 
 
feline          AGCGGTCCCCTCACCGGCCCATCCTGCAGGCGGGGTTGCCTGCCAACAAGACAGTGGCCC 
canine          AGCGGTCCCCTCACCGGCCCATCCTGCAGGCGGGGCTGCCTGCCAACAAGACAGTGGCCC 
human           AGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGGTTGCCCGCCAACAAAACAGTGGCCC 
                ****************************.**.*** **** ********.********** 
 
feline          TGGGCAGCAATGTGGAGTTCATGTGTAAGGTGTACAGTGACCCACAGCCCCATATCCAGT 
canine         TGGGCAGCAATGTGGAGTTCATGTGTAAGGTGTACAGTGACCCACAGCCGCATATCCAGT 
human           TGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTACAGTGACCCGCAGCCGCACATCCAGT 
                **** ***** ********************************.***** ** ******* 
 
feline          GGCTAAAGCACATCGAGGTGAATGGGAGTAAGATTGGTCCAGACAACCTGCCTTATGTCC 
canine          GGCTCAAGCACATCGAGGTGAATGGGAGTAAGATTGGTCCCGACAACCTGCCTTATGTCC 
human           GGCTAAAGCACATCGAGGTGAATGGGAGCAAGATTGGCCCAGACAACCTGCCTTATGTCC 
                ****.*********************** ******** **.******************* 
 
feline          AGATCTTGAAG 
canine          AGATCTTGAAG 
human           AGATCTTGAAG 
                *********** 
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FGFR1 Exon 7 (IIIb) 
 
 
feline          CATTCGGGGATTAATAGCTCGGATGCGGAGGTGCTGACCCTGTTCAATGTGACAGAGGCC 
human           CATTCGGGGATTAATAGCTCGGATGCGGAGGTGCTGACCCTGTTCAATGTGACAGAGGCC 
canine          CATTCGGGGATTAATAGCTCGGATGCGGAGGTGCTGACCTTATTCAATGTGACAGAGGCC 
                *************************************** *.****************** 
 
feline          CAGAGCGGGGAGTATGTGTGTAAGGTTTCCAATTATATTGGTGAAGCTAACCAGTCTGCG 
human           CAGAGCGGGGAGTATGTGTGTAAGGTTTCCAATTATATTGGTGAAGCTAACCAGTCTGCG 
canine          CAGAGCGGGGAGTATGTGTGTAAGGTTTCCAATTATATTGGTGAAGCTAACCAGTCTGCG 
                ************************************************************ 
 
feline          TGGCTCACTGTCACCAGACCTGTGGCAAAAG 
human           TGGCTCACTGTCACCAGACCTGTGGCAAAAG 
canine          TGGCTCACTGTCACCAGACCTGTGGCAAAAG 
                ******************************* 
 
 
FGFR1 Exon 8 (IIIc) 
 
 
feline         ACTGCCGGAGTTAACACCACCGACAAAGAGATGGAAGTGCTTCACTTAAGGAATGTCTCC 
canine          ACTGCCGGAGTTAATACCACCGACAAAGAGATGGAAGTGCTTCACTTAAGGAATGTCTCC 
human           ACTGCTGGAGTTAATACCACCGACAAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCC 
               ***** ******** ********************.**************.********* 
 
feline          TTTGAGGACGCGGGGGAGTATACGTGCTTGGCGGGTAACTCTATCGGACTGTCCCATCAC 
canine          TTTGAGGACGCGGGGGAGTATACGTGCTTGGCGGGTAACTCTATCGGACTCTCCCATCAC 
human           TTTGAGGACGCAGGGGAGTATACGTGCTTGGCGGGTAACTCTATCGGACTCTCCCATCAC 
                ***********.************************************** ********* 
 
feline          TCTGCATGGTTGACCGTTTTGGAAG 
canine         TCTGCATGGTTGACCGTTTTGGAAG 
human           TCTGCATGGTTGACCGTTCTGGAAG 
                ****************** ****** 
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FGFR1 Exon 9 
 
 
human           CCCTGGAAGAGAGGCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTATT 
canine          CCCTGGAAGAGAGGCCAGCAGCGATGACCTCGCCCCTATACCTGGAGATCATCATCTACT 
feline          CCCTGGAAGAGAGGCCGGCGGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTACT 
                ****************.**.* ***************.******************** * 
 
human           GCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCTACAAGATGAAGA 
canine          GCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGCTCTGTCATCATCTACAAGATGAAGA 
feline          GCACGGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCTGTCATCATCTACAAAATGAAGA 
                ****.***************************** ** ******.*******.******* 
 
human           GTGGTACCAAGAAGAGTGACTTCCACAGCCAGATGGCTGTGCACAAGCTGGCCAAGAGCA 
canine          GTGGCACCAAAAAGAGCGACTTCCACAGCCAAATGGCTGTGCACAAGCTGGCCAAGAGCA 
feline          GTGGCACCAAGAAGAGCGACTTCCACAGCCAGATGGCCGTGCACAAGCTGGCCAAGAGCA 
                **** *****.***** **************.***** ********************** 
 
human           TCCCTCTGCGCAGACAGGTAACA 
canine          TCCCTCTGCGCAGACAGGTAACA 
feline         TCCCGCTGCGCAGACAGGTAACA 
                **** ****************** 
 
 
FGFR1 Exon 10 
 
 
feline          GTGTCGGCTGATTCTAGTGCCTCCATGAACTCTGGGGTTCTGCTGGTTCGGCCCTCACGT 
canine          GTGTCGGCCGATTCTAGTGCATCCATGAACTCTGGGGTTCTGCTGGTTCGGCCCTCACGT 
human           GTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGGGTTCTTCTGGTTCGGCCATCACGG 
                ***** ** ** ** *****.******************** ***********.*****  
 
feline          CTCTCCTCTAGTGGAACCCCCATGCTGGCTGGGGTCTCTGAATATGAGCTTCCTGAAGAC 
canine         CTCTCCTCAAGTGGAACACCCATGCTGGCTGGGGTCTCTGAATATGAGCTTCCCGAAGAC 
human           CTCTCCTCCAGTGGGACTCCCATGCTAGCAGGGGTCTCTGAGTATGAGCTTCCCGAAGAC 
                ******** *****.** ********.**:***********.*********** ****** 
 
feline          CCACGCTGGGAGCTGCCTCGAGACAG 
canine          CCTCGCTGGGAACTGCCTCGAGACAG 
human           CCTCGCTGGGAGCTGCCTCGGGACAG 
                **:********.********.***** 
 
 
FGFR1 Exon 11 
 
 
feline          ---GCTGGTTTTAGGCAAACCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGA 
canine          AAGGCTGGTTTTAGGCAAACCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTATTGGCAGA 
human           ---ACTGGTCTTAGGCAAACCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGA 
                  .***** *****************************************.******** 
 
feline          GGCCATCGGGCTGGACAAGGACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTT 
canine          AGCCATTGGGCTGGACAAGGACAAACCCAACCGTGTGACCAAAGTGGCCGTGAAGATGTT 
human           GGCTATCGGGCTGGACAAGGACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTT 
                .** ** ***************************************** *********** 
 
feline          GAAGT 
canine          GAAGT 
human           GAAGT 
                ***** 
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FGFR1 Exon 12 
 
 
feline          CGGACGCAACAGAGAAAGACCTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGA 
human           CGGACGCAACAGAGAAAGACTTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGA 
canine          CGGATGCTACAGAGAAAGACCTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGA 
                **** **:************ *************************************** 
 
feline         TCGGGAAGCACAAGAACATCATCAACCTGCTGGGGGCCTGCACGCAGGACG 
human           TCGGGAAGCATAAGAATATCATCAACCTGCTGGGGGCCTGCACGCAGGATG 
canine          TCGGAAAGCACAAGAACATCATCAACCTGCTGGGGGCGTGCACGCAGGACG 
                ****.***** ***** ******************** *********** * 
 
 
FGFR1 Exon 13 
 
 
feline          GTCCATTGTACGTCATCGTGGAGTATGCCTCCAAAGGCAACCTACGGGAATACCTGCAGG 
canine          GTCCCTTGTATGTCATCGTGGAGTATGCTTCCAAAGGCAACTTACGGGAGTACCTGCAGG 
human           GTCCCTTGTATGTCATCGTGGAGTATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGG 
                ****.***** ***************** *****.****** *.*****.********** 
 
feline          CCCGGCGGCCCCCGGGGCTGGAGTACTGTTATAACCCCAGCCACAACCCAGAGGAGCAGC 
canine          CCCGGAGGCCTCCTGGGCTGGAGTACTGTTACAATCCCAGCCACAACCCAGAGGAGCAGC 
human          CCCGGAGGCCCCCAGGGCTGGAATACTGCTACAACCCCAGCCACAACCCAGAGGAGCAGC 
                *****.**** ** ********.***** ** ** ************************* 
 
feline          TCTCTTCCAAGGACCTGGTCTCCTGCGCCTATCAGGTGGCCCGAGGCATGGAGTATCTTG 
canine          TCTCCTCCAAGGACCTGGTATCCTGCGCCTATCAGGTGGCCCGAGGCATGGAATATCTCG 
human           TCTCCTCCAAGGACCTGGTGTCCTGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCTGG 
                **** ************** *********** ********************.***** * 
 
feline         CCTCCAAGAAG 
canine          CCTCAAAGAAG 
human           CCTCCAAGAAG 
                ****.****** 
 
 
FGFR1 Exon 14 
 
 
human           TGCATACACCGAGACCTGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAG 
canine          TGCATACACCGAGACCTGGCTGCCAGGAATGTGCTGGTGACGGAGGACAACGTGATGAAG 
feline          TGCATACACCGAGACCTGGCCGCCAGGAACGTCCTGGTGACAGAGGACAACGTGATGAAG 
                ******************** ******** ** ********.******** ********* 
 
human           ATAGCAGACTTTGGCCTCGCACGGGACATTCACCACATCGACTACTATAAAAAGACAACC 
canine          ATCGCAGACTTTGGCCTTGCAAGGGACATTCACCACATCGACTACTATAAAA-------- 
feline          ATCGCAGACTTCGGCCTCGCTCGGGACATCCACCATATTGACTACTATAAAAAGACAACC 
                **.******** ***** **:.******* ***** ** *************         
 
human          AAC 
canine          --- 
feline          AAT 
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FGFR1 Exon 15 
 
 
feline          ------------GCCGGCTCCCTGTGAAGTGGATGGCACCCGAGGCCTTGTTTGACCGGA 
human          -----------GGCCGACTGCCTGTGAAGTGGATGGCACCCGAGGCATTATTTGACCGGA 
canine          GCCACTTGCAGGGCCGGCTGCCTGTGAAGTGGATGGCACCTGAGGCCTTGTTTGACCGGA 
                            ****.** ******************** *****.**.********** 
 
feline          TCTACACCCACCAGAGTGACGT 
human           TCTACACCCACCAGAGTGATG- 
canine          TCTACACCCACCAGAGTGACGT 
                ******************* *  
 
 
FGFR1 Exon 16 
 
 
human           GTGGTCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCATACCCCGG 
canine          CTGGTCTTTTGGGGTGCTCCTTTGGGAAATCTTCACTCTGGGAGGCTCCCCGTATCCTGG 
feline          CTGGTCTTTTGGGGTGCTCCTGTGGGAAATCTTCACTCTGGGAGGCTCCCCGTATCCTGG 
                 ******** *********** *****.**************.********.** ** ** 
 
human           TGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGACAAGCCCAG 
canine         TGTGCCTGTGGAGGAGCTTTTCAAGCTGCTGAAGGAGGGTCATCGAATGGACAAGCCCAG 
feline          CGTGCCTGTGGAGGAGCTTTTCAAGCTGCTGAAGGAGGGTCATCGAATGGACAAGCCCAG 
                 **************.************************** **.************** 
 
human           TAACTGCACCAACGAGCT 
canine          TAACTGCACCAATGAACT 
feline          TAACTGCACCAATGAGCT 
                ************ **.** 
 
 
FGFR1 Exon 17 
 
 
feline          ATACATGATGATGCGGGATTGCTGGCATGCAGTACCCTCTCAGAGACCTACCTTCAAGCA 
human           GTACATGATGATGCGGGACTGCTGGCATGCAGTGCCCTCACAGAGACCCACCTTCAAGCA 
canine          GTACATGATGATGCGGGATTGCTGGCATGCAGTGCCCTCTCAGAGACCTACCTTCAAGCA 
                .***************** **************.*****:******** *********** 
 
feline          GCTGGTGGAAGACCTGGACCGCATTGTGGCCTTGACCTCCAACCAG 
human          GCTGGTGGAAGACCTGGACCGCATCGTGGCCTTGACCTCCAACCAG 
canine          GCTGGTGGAAGACCTGGATCGCATCGTGGCCTTGACCTCCAACCAG 
                ****************** ***** *********************  
 
 
FGFR1 Exon 18 
 
 
feline         GAGTATCTGGACCTGTCAATGCCCCTGGACCAATACTCTCCCAGCTTTCCCGACACCCGA 
canine          GAGTACCTGGACCTGTCAGTGCCCCTGGACCAATACTCTCCAAGCTTCCCTGACACCCGA 
human           GAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTCCCCCAGCTTTCCCGACACCCGG 
                ***** ***********..*************.***** **.***** ** ********. 
 
feline          AGCTCTACCTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCGTTGCCTGAGGAG 
canine          AGCTCCACCTGCTCCTCGGGGGAGGATTCCGTCTTCTCTCATGAGCCGTTGCCTGAGGAG 
human           AGCTCTACGTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCGCTGCCCGAGGAG 
               ***** ** ********.****************************** **** ****** 
 
feline          CCCTGTCTGCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGGCGCTGA 
canine         CCGTGTCTGCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGACGCTGA 
human           CCCTGCCTGCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGCCGCTGA 
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FGFR2 Exon 2 
 
human          AGCCACCAACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGT 
canine          ------------------------------------------------------GGGAAT 
feline          --CCGCCAACCAAATACCAAATCTCCCAACCTGAAGTTTACGTGGCCGCGCCCGGGGAGT 
                                                                      ****.* 
 
human           CGCTAGAGGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGG 
canine          CGCTAGAGTTGCGCTGTCTGTTGAGAGATGCCGCCACGATCATTTGGACTAAGGATGGGG 
feline          CGCTAGAATTGCGCTGTCCGTTGAGAGATGCCACCATGATCAGTTGGACTAAGGATGGGG 
                *******. ******* * *****.*******.**. ***** ***************** 
 
human           TGCACTTGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCG 
canine          TACACTTGGGGCCCAACAATAGGACAGTGCTTATTGGGGAATACTTGCAGATAAAAGGTG 
feline          TACACTTGGGGCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAAGGTG 
                *.**************************************.**************.** * 
 
human           CCACGCCTAGAGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAA 
canine          CCACGCCTAGAGACTCCGGCCTCTATGCTTGCACGGCGGCTAGGCCGGTAGACAGCGAGG 
feline          CCACGCCTAGAGACTCCGGCCTCTATGCTTGCACGGCGGCTAGGCCGGTAGACAGCGAGG 
                ******************************* ** ** . ****.* ******** **.. 
 
human           CTTGGTACTTCATGGTGAATGTCACAG 
canine          CTGTCTACTTCATGGTGAATGTCACAG 
feline          CTGTCTACTTCATGGTCAATGTCACAG 
                **   *********** ********** 
 
 
FGFR2 Exon 5 
 
feline          GTACGGAACCAGCACTGGAGTCTTATTATGGAGAGCGTGGTCCCATCTGACAAAGGCAAT 
canine          GTACGAAACCAGCACTGGAGCCTTATTATGGAGAGCGTGGTCCCATCCGACAAAGGAAAT 
human           GTACGAAACCAGCACTGGAGCCTCATTATGGAAAGTGTGGTCCCATCTGACAAGGGAAAT 
                *****.************** ** ********.** *********** *****.**.*** 
 
feline          TATACCTGTGTGGTGGAGAACGAGTATGGCTCTATCAATCACACGTACCACCTTGATGTT 
canine          TACACCTGTGTGGTAGAGAATGAGTATGGCTCCATTAATCACACGTACCACCTCGACGTC 
human           TATACCTGTGTAGTGGAGAATGAATACGGGTCCATCAATCACACGTACCACCTGGATGTT 
                ** ********.**.***** **.** ** ** ** ***************** ** **  
 
feline          GTTG 
canine          GTCG 
human           GTGG 
                ** * 
 
 FGFR2 Exon 6 
 
human           AGCGATCGCCTCACCGGCCCATCCTCCAAGCCGGACTGCCGGCAAATGCCTCCACAGTGG 
canine          AGCGATCGCCACACCGGCCCATCCTCCAAGCTGGGCTGCCGGCAAACGCCTCCACCGTGG 
feline          AGCGATCACCACACCGGCCCATCCTCCAGGCTGGACTGCCTGCCAATGCCTCCACCGTGG 
                *******.**:*****************.** **.***** **.** ********.**** 
 
human           TCGGAGGAGACGTAGAGTTTGTCTGCAAGGTTTACAGTGATGCCCAGCCCCACATCCAGT 
canine          TCGGAGGCGACGTGGAGTTTGTCTGCAAAGTTTACAGCGATGCCCAGCCCCACATTCAGT 
feline          TCGGAGGCGACGTGGAGTTTGTCTGCAAAGTTTACAGCGATGCCCAGCCCCACATTCAGT 
                *******.*****.**************.******** ***************** **** 
 
human           GGATCAAGCACGTGGAAAAGAACGGCAGTAAATACGGGCCCGACGGGCTGCCCTACCTCA 
canine          GGATCAAACACGTAGAAAAGAACGGGAGCAAATACGGGCCCGATGGGTTGCCGTACCTCA 
feline          GGATCAAACACGTGGAAAAGAACGGCAGCAAATACGGACCCGACGGGCTACCCTACCTCA 
                *******.*****.*********** ** ********.***** *** *.** ******* 
 
human           AGGTTCTCAAG 
canine          AGGTTCTCAAG 
feline          AGGTTCTGAAG 
                ******* *** 
 
 
Table 4.2: Feline FGFR2 exons – alignment with human and canine sequences 
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FGFR2 Exon 10 
 
feline          GTTTCTGCCGAGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACCACA 
canine          GTGTCTGCTGAGTCCAGCTCCTCTATGAACTCCAACACTCCGCTGGTGAGGATAACCACG 
human           GTTTCGGCTGAGTCCAGCTCCTCCATGAACTCCAACACCCCGCTGGTGAGGATAACAACA 
                ** ** ** ************** ************** *****************.**. 
 
feline          CGCCTCTCCTCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTACGAACTTCCA 
canine          CGCCTCTCCTCAACAGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTGCCG 
human          CGCCTCTCTTCAACGGCAGACACCCCCATGCTGGCAGGGGTCTCCGAGTATGAACTTCCA 
                ******** *****.*********************************** ***** **. 
 
feline          GAAGATCCAAAGTGGGAGTTTCCAAGAGATAA 
canine          GAAGATCCAAAGTGGGAGTTTCCCAGAGATAA 
human           GAGGACCCAAAATGGGAGTTTCCAAGAGATAA 
                **.** *****.***********.******** 
 
 FGFR2 Exon 11 
 
feline          GCTGACGCTGGGCAAACCTCTGGGGGAAGGTTGCTTTGGGCAAGTGGTCATGGCCGAAGC 
canine          GCTGACGCTGGGCAAACCTCTGGGGGAAGGTTGCTTTGGGCAAGTGGTCATGGCCGAAGC 
human           GCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGC 
                ******.********.** *****.***************************** ***** 
 
feline          AGTGGGGATTGACAAAGAGAAGCCCAAGGAAGCAGTCACCGTGGCAGTGAAGATGTTGAA 
canine         GGTGGGAATTGACAAAGAGAAGCCCAAGGAAGCAGTCACGGTGGCGGTGAAGATGTTGAA 
human           AGTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAA 
                .*****.*********** ***********.**.***** ***** ************** 
 
feline          AG 
canine          AG 
human           AG 
                ** 
 
FGFR2 Exon 12 
 
feline         ATGATGCCACAGAGAAGGATCTTTCTGATCTTGTGTCAGAGATGGAGATGATGAAGATGA 
human           ATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATGA 
canine          ACGATGCCACAGAGAAAGATCTTTCTGATCTAGTGTCAGAGATGGAGATGATGAAGATGA 
                * **************.** *********** **************************** 
 
feline          TTGGAAAACACAAAAATATCATAAATCTCCTGGGAGCCTGCACTCAGGATG 
human           TTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATG 
canine          TTGGAAAACACAAAAATATCATAAATCTCCTTGGAGCCTGTACTCAGGATG 
               ****.********.************** ** ******** **:******* 
 
FGFR2 Exon 13 
 
human           GGCCTCTCTATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAG 
canine          GCCCACTCTACGTCATTGTGGAGTATGCCTCGAAAGGCAACCTCCGTGAATACCTCCGAG 
feline          GGCCGCTCTATGTCATAGTTGAGTACGCCTCGAAGGGCAACCTCCGGGAATACCTCCGAG 
                * ** ***** *****:** ***** ***** **.*********** ************* 
 
human           CCCGGAGGCCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGA 
canine          CCCGGAGGCCGCCTGGGATGGAGTATTCCTATGACATTAACCGCGTTCCTGAGGAGCAGA 
feline         CCCGCAGGCCCCCCGGGATGGAGTACTCCTATGACATTAACCGCGTCCCCGAGGAGCAGA 
                **** ***** ** *********** ***************** ** ** ********** 
 
human           TGACCTTCAAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGG 
canine          TGACCTTTAAGGACTTGGTGTCGTGTACCTACCAGCTGGCGAGAGGCATGGAGTACTTGG 
feline          TGACCTTCAAGGACTTGGTGTCCTGCACCTACCAGCTGGCGAGAGGCATGGAATACCTGG 
                ******* ************** ** ************** ***********.*** *** 
 
human           CTTCCCAAAAA 
canine          CTTCCCAGAAA 
feline          CTTCCCAGAAA 
                *******.*** 
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FGFR2 Exon 14 
 
human           TGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATGAAA 
canine          TGTATTCATCGGGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATGAAA 
feline          TGCATTCATCGAGATTTAGCCGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATGAAA 
                ** ********.********.*************************************** 
 
human          ATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACCACC 
canine          ATAGCAGACTTTGGACTGGCCAGAGATATCAACAATATAGACTATTACAAAAAGACCACA 
feline          ATAGCAGACTTTGGACTGGCCAGAGATATCAACAATATAGACTATTACAAAAAGACCACA 
               ***************** *****************************************. 
 
human           AAT 
canine          AAT 
feline          AAC 
                **  
 
FGFR2 Exon 15 
 
 
feline         GGACGACTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTTTTCGATCGAGTGTACACCCAC 
canine          GGGCGACTTCCGGTCAAGTGGATGGCTCCAGAAGCCCTTTTCGATCGAGTGTACACCCAT 
human           GGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATACACTCAT 
                **.**.*****.************************** ** ***.****.***** **  
 
feline          CAGAGTGACGT 
canine          CAGAGTGACGT 
human           CAGAGTGATGT 
               ******** ** 
 
FGFR2 Exon 16 
 
feline          TTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTGGGAGGTTCACCCTACCCAGG 
canine          TTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACGCTGGGGGGCTCACCATACCCAGG 
human           CTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGGGGCTCGCCCTACCCAGG 
                 ***********************************  *.**.** **.**.******** 
 
feline          GATTCCGGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGGATGGACAAGCCGGC 
canine          GATTCCGGTGGAGGAACTATTTAAGCTGCTCAAGGAGGGGCACAGGATGGACAAGCCAGC 
human           GATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACACAGAATGGATAAGCCAGC 
                ****** ***********:*********** *****.**.*****.***** *****.** 
 
feline          AAACTGCACCAATGAACT 
canine          AAACTGCACCAATGAACT 
human           CAACTGCACCAACGAACT 
                .*********** ***** 
 
FGFR2 Exon 17 
 
feline          GTATATGATGATGAGGGATTGTTGGCACGCCGTGCCCTCACAGAGGCCGACGTTCAAACA 
human           GTACATGATGATGAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCA 
canine          GTATATGATGATGAGGGACTGTTGGCATGCTGTGCCCTCACAGAGGCCGACGTTCAAGCA 
                *** ************** ******** ** ********.*****.**.********.** 
 
feline          GTTGGTGGAAGACTTGGACCGAATTCTCACTCTCACCACCAACGAG 
human           GTTGGTAGAAGACTTGGATCGAATTCTCACTCTCACAACCAATGAG 
canine          GTTGGTAGAGGACTTGGATCGGATTCTCACTCTCACAACCAATGAG 
               ******.**.******** **.**************.***** *** 
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FGFR2 Exon 18 
 
feline          GAATACTTGGACCTCAGTCAGCCTCTCGAACAGTATTCACCTAGTTACCCTGACACAAGG 
canine          GAATACTTGGACCTCAGTCAGCCTCTCGAACAGTATTCACCTAGTTATCCTGACACAAGG 
human           GAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCACCTAGTTACCCTGACACAAGA 
                ***************** **.************************** ***********. 
 
feline         AGTTCTTGTTCTTCAGGAGACGATTCTGTTTTCTCTCCGGACCCCATGCCTTACGAACCA 
canine          AGTTCGTGTTCTTCAGGAGACGATTCTGTTTTCTCTCCAGACCCCATGCCTTACGAACCA 
human           AGTTCTTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCAGACCCCATGCCTTACGAACCA 
                ***** ************** *********** *****.********************* 
 
feline          TGCCTTCCTCAGTATCCACATGTAAACGGCAGTGTTAAAACATGA 
canine          TGCCTTCCTCAGTATCCACATGTAAACGGCAGTGTTAAAACATGA 
human           TGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAAACATGA 
               ******************** .*********************** 
 
FGFR3 Exon 1 
 
feline          --GCCCCGGGACCTGAGCCCGGCCCGCAGGAGCAGCTGGTCTTTGGCAGCGGGGACACCG 
human           AAGTCCCGGGCCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTG 
canine          --ACCCCGGGACCTGAGCCTGGCCAGCAGGAGCCACTGGTCTTTGGCAGCGGGGACACTG 
                 . ******.**:***** ****.********.. ******* *********** .* * 
 
feline          TGGAGCTGAGCTGCCACTTGCCTGCAGGTGGCCCCACAGGGCCCAGCGTATGGGTCAAGG 
human          TGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGG 
canine          TGGAGCTGACCTGCCCCTCACCTATAGACAGTCCCACAGGGCCCAGCATCTGGGTCAAGG 
                ********* *** *.*  .** . .*. .* **** .*******  .*.********** 
 
feline          ACGGTGTGGGGCTGGCGCCCTCAGACCGCATCCTGGTGGGGCCTCAGCGGCTGCAGGTGC 
human           ATGGCACAGGGCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGC 
canine          ATGGTGTGGGGCTGGTGCCCTCAGACCGCATCCTGGTGGGGCCTCGGCGGCTGCAGGTAC 
                * ** . .******* ******.** ** .************* *.************.* 
 
feline          TGAATGCCTCCCACGAGGACACGGGGGCCTACAGCTGCCGGCAGCGGCTTACCCAGCGCG 
human           TGAATGCCTCCCACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCG 
canine          TCAATGCCTCCCATGAGGATGCTGGGACCTACAGCTGCCGGCAGCGGCTCACCCAGCGCA 
                * *********** *****  * ***.********************** ** ******. 
 
feline          TGCTATGCGACTTCAGCGTGCGCGTGACAG 
human           TACTGTGCCACTTCAGTGTGCGGGTGACAG 
canine          TCCTGTGCCATTTCAGCGTGCGTGTGACAG 
                * **.*** * ***** ***** ******* 
 
Table 4.3: Feline FGFR3 exons – alignment with human and canine sequences 
FGFR3 Exon 10 
 
feline          CCGAGGAGGAGCTGCTGGAGGCCGGCGCGGCGGGCAGCGTGTATGCGGGCGTCCTCAGCT 
canine         CCGAGGAGGAGCTGGTGGAGGCTGGTGAGGCTGGCAGCGTGTACGCAGGTGTCCTCAGCT 
human           CCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATGCAGGCATCCTCAGCT 
                ************** ******* *. *.*** ***** ***** **.** .********* 
 
feline          ACGGGGCGGGCTTCCTCCTCTTCATCCTGGTGGTGGCCGCCGTGACACTGTGCCGTCTGC 
canine          ACGGGGTGGGCTTCCTCCTCTTCATCCTGGTGGTGGCAGCTGTGACACTGTGCCGTCTGC 
human           ACGGGGTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGC 
                ****** ******* **** ***************** ** *****.** ***** **** 
 
feline          ACAGTCCCCCGAAGAAGGGCCTGGGCTCGCCCACCGTGCACAAGGTCTCCCGCTTTCCAC 
canine          GCACTCCCCCGAAGAAGGGCCTGGGCTCGCCTACCGTGCACAAGGTCTCCCGCTTTCCAC 
human           GCAGCCCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGC 
                .**  ***** *****.*********** ** ************.********** **.* 
 
feline          TCAAGCGACAG 
canine          TCAAGCGACAG 
human           TCAAGCGACAG 
                *********** 
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Table 4.4: Feline FGFR4 exonic sequences (red underlined upper case) with their 




















FGFR3 Exon 11 
 
human           GTGTCCCTGGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGG 
canine          GTGTCCTTGGAGTCCAACTCGTCCATGAACTCTAACACGCCACTGGTGCGTATCGCCCGG 
feline          GTGTCCTTGGAGTCCAACTCGTCCATGAACTCCAACACGCCGCTGGTGCGAATCGCCCGG 
                ****** *********** *********.*** *****.**.******** *****..** 
 
human          CTGTCCTCAGGGGAGGGCCCCACGCTGGCCAATGTCTCCGAGCTCGAGCTGCCTGCCGAC 
canine          CTGTCTTCTGGGGAGGGCCCTGCACTGGCCAACGTCTCTGAGCTGGAGCTGCCTGCTGAC 
feline          CTGTCTTCCGGGGAGGGTCCTGCGCTGGCCAACGTCTCCGAGCTCGAGCTGCCCGCCGAC 
               ***** ** ******** ** .*.******** ***** ***** ******** ** *** 
 
human           CCCAAATGGGAGCTGTCTCGGGCCCG 
canine          CCCAAGTGGGAGCTGTCCAGGGCCCG 
feline          CCCAAGTGGGAGCTATCCAGGGCCCG 
                *****.********.** .******* 
 
FGFR3 Exon 12 
 
feline          GCTGACCCTGGGCAAGCCTCTCGGGGAGGGCTGCTTTGGCCAAGTGGTCATGGCAGAGGC 
canine          GCTGACCCTAGGCAAGCCTCTTGGGGAAGGCTGCTTTGGCCAGGTGGTCATGGCAGAGGC 
human           GCTGACCCTGGGCAAGCCCCTTGGGGAGGGCTGCTTCGGCCAGGTGGTCATGGCGGAGGC 
                *********.******** ** *****.******** *****.***********.***** 
 
feline          CATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACTGTGGCCGTGAAGATGCTGAA 
canine          CATCGGTATTGACAAGGACCGGGCTGCCAAGCCTGTCACTGTGGCTGTGAAGATGCTAAA 
human          CATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGTAGCCGTGAAGATGCTGAA 
                ****** ***************** ************** **.** ***********.** 
 
feline          AG 
canine          AG 
human           AG 
                ** 
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4.2  Relative expression of Fibroblast growth factor receptors 1-3 IIIb-
IIIc isoforms and FGFR4. 
 
4.2.1 Cell lines:  
Four ISSa and two non-ISSa cell lines were evaluated in this study.  
 100% (n=4) of the ISSa and 100% (n=2) of the non-ISSa expressed 
(Ct<35.00) FGFR1 IIIb, FGFR1 IIIc and FGFR4.  
 75% (n=3) of ISSa and 50% (n=1) of non-ISSa expressed FGFR2 IIIb.  
 75% (n=3) of ISSa and 100% (n=2) of non-ISSa expressed FGFR2 IIIc.  
 50% (n=2) of ISSa and 100% (n=2) of non-ISSa expressed FGFR3 IIIb.  
 75% (n=3) of ISSa and 100% (n=2) of non-ISSa expressed FGFR3 IIIc. 
No statistical difference was found in the expression levels of each target 
gene between ISSa and non-ISSa (Graphic 4.2). 
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Graphic 4.2: Relative expression ratio of FGFR1-4 in ISSa vs non-ISSa cell 
lines. Boxes represents the interquartile range, or the middle 50% of 
observations. The dotted line represents the median gene expression. 
Whiskers represent the minimum and maximum observations. (REST) 
 
  
Gene Expression Std. Error 95% C.I. P(H1) 
FGFR1 IIIb 2,763 0,484 - 18,825 0,259 - 28,185 0,552 
FGFR1 IIIc 1,250 0,566 - 6,036 0,158 - 9,059 0,891 
FGFR2 IIIb 19,738 1,399 - 480,673 0,094 - 695,498 0,369 
FGFR2 IIIc 90,549 8,227 - 2.241,249 0,175 - 4.249,810 0,310 
FGFR3 IIIb 0,300 0,166 - 0,549 0,130 - 0,711 0,080 
FGFR3 IIIc 0,934 0,269 - 2,360 0,120 - 3,579 0,966 
FGFR4 1,691 0,819 - 5,582 0,370 - 6,234 0,528 
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4.2.2 Frozen tumor samples: 
 
Five ISSa and three non-ISSa frozen tumor samples were evaluated 
in this study.  
 100% (n=5) of the ISSa and 100% (n=3) of the non-ISSa expressed 
(Ct<35.00) FGFR1 IIIb, FGFR1 IIIc and FGFR4.  
 80% (n=4) of ISSa and 100% (n=3) of non-ISSa expressed FGFR2 IIIb.  
 100% (n=5) of ISSa and 100% (n=3) of non-ISSa expressed FGFR2 IIIc.  
 20% (n=1) of ISSa and 0% (n=0) of non-ISSa expressed FGFR3 IIIb.  
 60% (n=3) of ISSa and 0% (n=0) of non-ISSa expressed FGFR3 IIIc. 
No statistical difference was found in the expression levels of each 
target gene between ISSa and non-ISSa (Table 4.6). 
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Graphic 4.4: Relative expression ratio of FGFR1-4 in ISSa vs non-ISSa frozen 
tumor samples. Boxes represents the interquartile range, or the middle 50% 
of observations. The dotted line represents the median gene expression. 
Whiskers represent the minimum and maximum observations. (REST) 
 
Gene Expression Std. Error 95% C.I. P(H1) 
FGFR1 IIIb 7,250 1,147 - 53,264 0,432 - 148,183 0,125 
FGFR1 IIIc 3,135 0,446 - 48,696 0,361 - 75,915 0,347 
FGFR2 IIIb 1,493 0,024 - 27,216 0,012 - 46,891 0,859 
FGFR2 IIIc 4,412 0,143 - 19,228 0,107 - 114,396 0,198 
FGFR3 IIIb 0,460 0,232 - 0,957 0,198 - 1,423 0,095 
FGFR3 IIIc 0,926 0,558 - 1,648 0,428 - 2,921 0,831 
FGFR4 1,470 0,565 - 4,570 0,273 - 12,140 0,654 
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4.2.3 FFPE samples: 
39 ISSa and 10 non-ISSa FFPE samples were evaluated in this study.  
 43,5% (n=17) of ISSa and 30% (n=3) of non-ISSa expressed 
(Ct<35.00) FGFR1 IIIb 
 25,6% (n=10) of ISSa and 30% (n=3) of non-ISSa expressed 
FGFR1 IIIc. 
 38,4% (n=15) of ISSa and 40% (n=4) of non-ISSa expressed 
FGFR2 IIIb.  
 15,3% (n=6) of ISSa and 20% (n=2) of non-ISSa expressed 
FGFR2 IIIc.  
 7,6% (n=3) of ISSa and 0% (n=0) of non-ISSa expressed FGFR3 
IIIb.  
 17,9% (n=7) of ISSa and 10% (n=1) of non-ISSa expressed 
FGFR3 IIIc. 





















FFPE Ct mean values
ISSa
non-ISSa
   Graphic 4.5: Ct mean values in ISSa and non-ISSa FFPE samples 
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Statisical analysis was performed for each target gene combining the 
results of ISSa and non-ISSa cell lines and frozen tumor samples with the 
ISSa and non-ISSa FFPE samples which expressed the evaluated gene. No 
statistical difference was found in the expression levels of FGFR1 IIIb-IIIc, 
FGFR2 IIIb, FGFR3 IIIb-IIIc and FGFR4. FGFR2 IIIb was up-regulated in ISSa 
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Graphic 4.6: Relative expression ratio of FGFR1 IIIb-IIIc between ISSa and 
non-ISSa cell lines, frozen tumor samples and FFPE samples. Boxes 
represents the interquartile range, or the middle 50% of observations. The 
dotted line represents the median gene expression. Whiskers represent the 
minimum and maximum observations. (REST) 
 
Gene Expression Std. Error 95% C.I. P(H1) 
FGFR1 IIIb 4,848 0,196 - 130,284 0,006 - 1.834,929 0,099 
FGFR1 IIIc 1,456 0,092 - 20,222 0,016 - 122,402 0,625 
Table 4.7: Statistical analysis results of ISSa and non-ISSa cell lines, frozen 
tumor samples and FFPE samples. (REST) 
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Graphic 4.7: Relative expression ratio of FGFR2 IIIb-IIIc between ISSa and 
non-ISSa cell lines, frozen tumor samples and FFPE samples. Boxes 
represents the interquartile range, or the middle 50% of observations. The 
dotted line represents the median gene expression. Whiskers represent the 
minimum and maximum observations. (REST) 
 
Gene Expression Std. Error 95% C.I. P(H1) 
FGFR2 IIIb 0,538 0,010 - 61,953 0,001 - 1.808,575 0,604 
FGFR2 IIIc* 11,174 0,316 - 416,163 0,098 - 4.111,523 0,028 
Table 4.8: Statistical analysis results of ISSa and non-ISSa cell lines, frozen 
tumor samples and FFPE samples. (REST). *Up-regulated in ISSa 
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Graphic 4.8: Relative expression ratio of FGFR3 IIIb-IIIc between ISSa and 
non-ISSa cell lines, frozen tumor samples and FFPE samples. Boxes 
represents the interquartile range, or the middle 50% of observations. The 
dotted line represents the median gene expression. Whiskers represent the 
minimum and maximum observations. (REST) 
 
Gene Expression Std. Error 95% C.I. P(H1) 
FGFR3 IIIb 14,095 0,671 - 309,483 0,425 - 555,380 0,375 
FGFR3 IIIc 7,578 0,446 - 292,142 0,022 - 15.721,933 0,306 
Table 4.9: Statistical analysis results of ISSa and non-ISSa cell lines, frozen 
tumor samples and FFPE samples. (REST).  
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Graphic 4.9: Relative expression ratio of FGFR4 in ISSa compared to non-ISSa 
cell lines, frozen tumor samples and FFPE samples. Boxes represents the 
interquartile range, or the middle 50% of observations. The dotted line 
represents the median gene expression. Whiskers represent the minimum 
and maximum observations. (REST) 
 
Gene Expression Std. Error 95% C.I. P(H1) 
FGFR4 2,295 0,061 - 111,459 0,002 - 1.366,977 0,453 
Table 4.10: Statistical analysis results of ISSa and non-ISSa cell lines, frozen 
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5. Discussion and conclusions 
 
 
Fibroblast growth factor receptors are signaling molecules involved 
in many physiological processes. Increasing evidences showed that gene 
mutations, up-regulation of FGFRs and exon switching from the IIIb to the 
IIIc splice variant are related to the pathogenesis and progression of several 
types of cancers. However, these studies have mainly been conducted in 
epithelial tumors. The low incidence of sarcomas in humans is one of the 
factors that limited the investigation of the FGFRs signaling in sarcomas.  
In the present study the relative expression levels of FGFR1-4 were 
evaluated in feline injection site sarcomas. Compared to spontaneous feline 
sarcomas, ISSa show a more malignant behavior, with increased local 
invasion and metastasis. The current standard treatment, which includes 
extensive surgical excision together with pre-operative radiotherapy, 
usually improves survival and time to first event, but the percentage of cats 
who achieve long term control is still less than 50% (Hauck, 2003). At the 
same time, this invasive treatment approach undoubtedly cause a condition 
of discomfort to the animals. The understanding of the molecular basis of 
malignant transformation in these tumors is critical to the development of 
new therapeutic approaches with the potential benefices to improve the 
animals‟ outcome and reduce the level of discomfort.  
The feline genome, differently from the human and canine genome, 
is not completely sequenced. There are long unknown sequences especially 
for the FGFR2 and FGFR3. The results obtained from the genomic DNA 
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sequencing confirmed the predicted sequences published on  the Ensembl 
database (accession numbers: ENSFCAG00000013612, ENSFCAG00000003692, 
ENSFCAG00000018385 ENSFCAG00000016224) and completed some of the 
unknown regions for each gene. Sequence alignment analysis with the 
human and canine nucleotide sequences indicated a remarkable 
conservation in both the number and arrangement of the intron/exon 
boundaries for FGFR1-3. The sequencing obtained for FGFR4 confirmed the 
Ensembl predicted sequence as well, although the reported number and 
arrangement of the intron/exon boundaries appeared different from the 
respective human and canine genes.  
The expression levels of fibroblast growth factor receptors were first 
evaluated in ISSa and non-ISSa cell lines. The analysis was then performed 
on frozen tumor samples to ensure that the data obtained on cell lines were 
not the result of in vitro culture. The results showed that the expression of 
FGFR1-4 is a common feature for both ISSa and non-ISSa. Particularly, 
FGFR1 IIIb-IIIc and FGFR4 were expressed in 100% of the ISSa and non-ISSa 
cell lines and tumor samples. FGFR3IIIb and IIIc were less frequently 
expressed.  Relative expression analysis in these samples suggested a 
differential expression of FGFR2 IIIc between ISSa and non-ISSa although no 
statistical difference was found.  
The investigation of the expression levels of FGFRs in 39 ISSa and 10 
non-ISSa FFPE samples was also performed. The results showed that FGFRs 
were overall expressed in a low percentage of samples.  Extracting RNA 
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from FFPE samples offers the advantage to molecularly study archival 
samples with known clinical outcome. However, obtaining a good quality 
RNA from these samples in terms of concentration, purity and integrity still 
remains a challenge. Despite the preservation of the morphological 
integrity of the tissues, FFPE samples undergo to degradation of nucleic 
acids, predominantly RNA, and the formalin fixation process creates cross-
linking between nucleic acids and proteins. To the author‟s opinion, these 
factors resulted in an underestimation of the frequency of expression and 
the expression levels of FGFRs in FFPE samples.  
FGFR2 IIIc is related to epithelial to mesenchymal transition in 
human prostate and bladder cancer and leads to a more invasive tumor 
phenotype. The role of this receptor isoform in sarcomas in still unknown. 
Interestingly, statistical analysis of the ISSa compared to non-ISSa 
including cell lines, frozen tumor samples and FFPE showed that FGFR2 IIIc 
is up-regulated in ISSa (p=0.028).  
In conclusion, this study demonstrated that fibroblast growth factor 
receptors are  expressed in feline sarcomas with a high frequency of 
expression of FGFR1 IIIb-IIIc and FGFR4. FGFR2 IIIc is up-regulated in ISSa 
compared to non-ISSa. Further investigation is needed to assess whether  
the up-regulation of FGFR2 IIIc in ISSa is related to the more aggressive 
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